Trial | NCT02094703  Report issue

Title

The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females
The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Symptomatic Non-complicated Urinary Tract Infection in Females

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    levofloxacin solifenacin ...

  • Study Participants

    126
The efficacy of Solifenacin Succinate 5 mg as adjuvant therapy and levofloxacin (500 mg) for short-term treatment to reduce symptoms in patients with symptomatic non complicated urinary tract infection in females.
Study Started
Apr 30
2013
Primary Completion
Nov 30
2014
Anticipated
Study Completion
Dec 31
2014
Anticipated
Last Update
Mar 24
2014
Estimate

Drug Levofloxacin

  • Other names: neslav

Drug Solifenacin succinate

Drug Placebo (for Solifenacin succinate)

levofloxacin and solifenacin succinate Experimental

Levofloxacin 500 mg tablet and solifenacin succinate 5 mg tablet by mouth once daily for 3 days

levofloxacin and placebo Active Comparator

Levofloxacin 500 mg tablet and placebo (for solifenacin succinate) by mouth once daily for 3 days

Criteria 

Inclusion Criteria:

females (18-65 years old)
dysuria in symptomatic non complicated urinary tract infection

Exclusion Criteria:

Pediatric Patients (< 18 years old)
geriatric Patients (> 65 years old)
pregnant Patients
Patients with complicated urinary tract infection
sexually transmitted infections
Patients with pathological abnormalities in the urinary bladder, including stone/mass
Catheter-mounted
Neurological diseases/disorders
patients with allergy/hypersensitivity with Levofloxacin/Solifenacin
No Results Posted